Find uplifting stories about heroes, innovations, and solutions
16 results for "kras"
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
A new pill called daraxonrasib has doubled survival time for advanced pancreatic cancer patients in a groundbreaking 500-person trial. Oncologists are calling it a grand slam after four decades of failed attempts to crack the disease.
An experimental once-daily pill nearly doubled survival time for patients with advanced pancreatic cancer, offering hope for one of the deadliest forms of the disease. The breakthrough targets a mutation present in over 90% of pancreatic tumors that scientists have struggled to treat for four decades.
Scientists have finally cracked a genetic mutation once thought impossible to treat, potentially transforming outcomes for 90% of pancreatic cancer patients. A new drug targeting KRAS mutations has doubled survival time compared to traditional chemotherapy.
A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy. The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases. --- ##
A revolutionary drug just doubled survival time for patients with advanced pancreatic cancer, one of the deadliest forms of the disease. Doctors are calling it unprecedented, and the breakthrough could soon help patients with lung, colorectal, and other cancers too.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A breakthrough medication targeting a previously "undruggable" genetic mutation could transform treatment for one of the deadliest cancers. Patients in late-stage trials lived nearly twice as long when taking the new drug alongside chemotherapy.
A breakthrough drug from Revolution Medicines is giving real hope to pancreatic cancer patients for the first time in decades. The pill, called daraxonrasib, successfully targeted KRAS, a protein scientists once thought was impossible to drug.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
University of Pennsylvania researchers eliminated precancerous pancreatic cells in mice before they became tumors, nearly doubling survival time. It's the first proof that medical intervention can stop pancreatic cancer at its earliest stage.
%2Fhttps%3A%2F%2Ftf-cmsv2-smithsonianmag-media.s3.amazonaws.com%2Ffiler_public%2F6e%2F57%2F6e57732e-0e31-405f-b3c9-349c613b16e2%2Fkrasner_combat_1965.jpg)
For decades, Lee Krasner was known mainly as Jackson Pollock's wife, even though she was the more accomplished artist when they met. Now the Met Museum is finally presenting them as equals in a groundbreaking exhibition.
Northwestern University researchers developed a breakthrough therapy that grabs "undruggable" cancer proteins and drags them to the cell's trash system for destruction. The approach worked against MYC and KRAS, two proteins that drive many aggressive cancers and resist most treatments.
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
A new triple therapy treatment completely eliminated pancreatic tumors in mice, offering hope for one of the deadliest cancers. The breakthrough could transform treatment for the 67,000 Americans diagnosed each year.
Researchers in Spain have found a triple-drug combination that eliminates pancreatic tumors in mice without them returning. The breakthrough could eventually transform treatment for one of cancer's deadliest forms.